HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Firm Hopes To Drill Into U.S. Market With Anti-Dandruff Ingredient

This article was originally published in The Rose Sheet

Executive Summary

Dermatology ingredient manufacturer Ichthyol-Gesellschaft is looking to introduce sodium shale oil sulfonate into FDA's OTC monograph as an ingredient that is generally recognized as safe and effective in treating dandruff

You may also be interested in...



Environmental Group Opposes FDA Addition Of Triclosan To OTC Monographs

An environmental group's efforts to block all non-medical uses of triclosan - including in OTC products - may be futile due to provisions in the National Environmental Policy Act of 1969

Environmental Group Opposes FDA Addition Of Triclosan To OTC Monographs

An environmental group's efforts to block all non-medical uses of triclosan - including in OTC products - may be futile due to provisions in the National Environmental Policy Act of 1969

Valeant nabs Australian skin care

Aliso Viejo, Calif.-based Valeant Pharmaceuticals International announces agreement to buy skin-care firm Private Formula International Holdings Pty Limited for approximately $69 million. With deal Valeant gains global rights to top-selling Australian skin-care line Dr. LeWinn's, new anti-aging Hissyfit products, and nail-strengthener line Revitanail, called Renunail in the U.S. and U.K. Dr. LeWinn's has distribution in more than 2,500 pharmacies and annual sales of $27 million. Valeant will issue 162,500 shares of its common stock as part of the deal, which will be escrowed for four years subject to Valeant indemnity claims. "The acquisition will allow Valeant Australia to become a leading dermatology company in Australia with brands that are complementary to our current portfolio and will dramatically increase our presence in the pharmacy over-the-counter channel," stated Valeant Chair and CEO J. Michael Pearson. The transaction is expected to close in early October. Valeant has expanded its dermatology holdings through recent acquisitions of Dow Pharmaceutical Sciences and Coria Laboratories (1"The Rose Sheet" April 13, 2009; 2"The Rose Sheet" Sept. 22, 2008)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel